Company / Net Income
aTYR PHARMA INC Net Income History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$74.1M
FY2025
5-year range
-$74.1M / -$16.2M
FY2021-FY2025
Trend
-15.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has declined for 3 consecutive years, from -$16M in FY2022 to -$74M in FY2025.
Based on SEC 10-K filings.
-$74M in FY2025.
Declined from -$34M to -$74M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- aTYR PHARMA INC's net income has declined for 3 consecutive years.
- In FY2025, net income decreased 15.8% year-over-year.
- Peak net income was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$74.1M | -15.8% |
| FY2024 | -$64.0M | -89.6% |
| FY2023 | -$33.8M | -108.1% |
| FY2022 | -$16.2M | +31.3% |
| FY2021 | -$23.6M | +31.6% |
| FY2020 | -$34.5M | +28.4% |
| FY2019 | -$48.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026